



Advanced Neuroendocrine Tumors

Guest Editor:

Dr. Rohini Sharma

Clinical Pharmacology and
Medical Oncology, Imperial
College London, London, UK

Deadline for manuscript
submissions:

closed (20 October 2022)

Message from the Guest Editor

Dear Colleagues,

Neuroendocrine tumors (NETs) are a clinically heterogeneous group of cancers, arising from the cells of endocrine glands (pituitary, adrenals and parathyroid), as well as neuroendocrine cells in the diffuse neuroendocrine system. Whilst considered to be a rare disease, the incidence of NETs has increased dramatically over the past 30 years, and unlike most other solid tumors, the incidence continues to rise.

Recently, there have been exciting changes in the management of NETs, with the introduction of peptide receptor radiotherapy, which has changed the treatment landscape, and there are a number of clinical trials investigating the utility of immunotherapy in this field.

In this Special Issue, we will bring together expertise in epigenetics, imaging and immunotherapy in addressing the evolving field of NETs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)